TB-500: a beginner's guide to the recovery peptide

Key takeaways

• TB-500 is a lab-made peptide, a 7-amino-acid piece (Ac-LKKTETQ) of a natural body protein called thymosin beta-4, which is 43 amino acids long . It has no FDA-approved medical use .
• The evidence people cite is not really about TB-500. It comes from animal studies of full-length thymosin beta-4, mostly in mice, which is what put the protein into early tissue-repair trials . A Banned Substances Control Group review found no controlled human trials of the TB-500 fragment itself .
• Even the animal case is shakier than the marketing suggests. One mouse study found thymosin beta-4 given after a heart attack did not regenerate heart muscle, and the authors flagged that as a caution for using it in people .
• It is banned for tested athletes at all times. WADA and USADA list thymosin-beta-4 and its derivatives, including TB-500, as prohibited growth factors under class S2.3 .
• The FDA names TB-500 as a compounding safety risk, with no human exposure data on record and a warning that it may cause immune reactions and carry peptide impurities . An advisory committee reviews it on July 23-24, 2026, but a spot on that agenda is a review step, not approval .

The short version: a strong animal story, on a different molecule

TB-500 is a synthetic peptide sold as a research chemical, not a medicine. Its sequence (Ac-LKKTETQ) copies a small active stretch, residues 17 to 23, of thymosin beta-4, a protein your body already makes . That stretch is the part that binds actin, a building-block inside cells involved in movement and repair .

People inject it under the skin or into muscle, often alongside BPC-157 in what the community calls the healing stack. Whichever way it goes in, the starting point is the same: an unapproved compound whose reputation is borrowed from a bigger molecule.

What people actually use it for

In recovery and gym circles, TB-500 is a go-to pick for stubborn tendon, ligament, and joint injuries. People reach for it hoping to speed up healing from strains and nagging joint pain, most often stacked with BPC-157. The user reports describe faster recovery.

Almost all of that is anecdote. These are personal accounts and community habits, not results from human trials, and the commercial claims mostly point back to animal work on thymosin beta-4 rather than a TB-500 evidence base of its own .

What the science actually shows: preclinical, and mostly not on TB-500

The evidence sits at the preclinical tier, which means animals, not people. The tissue-repair reputation traces to studies of full-length thymosin beta-4 in animal models, and that work is what put the protein into early wound-repair trials in the first place .

Where the animal data get tested hard, they get mixed. In one mouse study, thymosin beta-4 after a heart attack reduced deaths from cardiac rupture and improved heart function, partly through anti-inflammatory effects and less scar-tissue remodeling .

A separate mouse study found the protein did not turn nearby cells into new heart-muscle cells at all, and the authors flagged that as a caution for anyone hoping to move it to people .

For the TB-500 fragment people actually buy, the human evidence base is empty. A Banned Substances Control Group review found no controlled human trials and no peer-reviewed safety studies of it . So the honest read is a decent animal story about a related molecule, and a lot of forum confidence filling the space where human data should be.

The catch: not approved, banned in sport, and an uncertain vial

• Not approved, and under review rather than settled: there is no FDA-approved TB-500, and as a Category 2 substance it is not permitted for 503A pharmacy compounding . An FDA advisory committee is scheduled to review TB-500 (free base and acetate), along with BPC-157, KPV, and MOTS-c, on July 23-24, 2026, but a spot on that agenda is a review step, not approval .
• Banned in sport: WADA and USADA list thymosin-beta-4 and its derivatives, including TB-500, as prohibited growth factors under section S2.3 . It is prohibited at all times, in and out of competition, and it is a non-Specified Substance, so a positive test can carry a significant sanction .
• You may not be buying TB-500 at all: the product sold is a protein fragment, not the full natural protein, so what is actually in the vial is uncertain . Independent testing of gray-market vials has turned up contaminants including endotoxins, truncated or incomplete peptide sequences, residual solvents, heavy metals, microbial contamination, and degradation products . The FDA points to the same peptide-impurity and aggregation problems .
• The regeneration claim is not established, even in animals: a mouse study found thymosin beta-4 after a heart attack did not create new heart-muscle cells, which is the opposite of the regrow-the-tissue story the marketing implies .
• Side effects people report: the most common are reactions at the injection site and temporary fatigue. Stop and get checked for any sign of an allergic reaction, chest or heart symptoms, or unexplained illness that spreads through the body.

How people take it, and where the real numbers live

If you are going to use it, the goal is doing it as cleanly as the unknowns allow. The usual route is a small subcutaneous or intramuscular injection, often a loading phase for the first few weeks and then less-frequent maintenance. TB-500 ships as a freeze-dried powder that you mix with liquid (usually bacteriostatic water) before drawing a dose.

None of the careful handling matters if the vial does not contain what the label says, and the research-chemical channel rarely comes with independent testing. A certificate of analysis from an accredited third-party lab is the one thing that turns an assumption into a check, which is exactly why the purity flag above is the part that protects you.

Where to read more

This guide is the on-ramp. For the deeper reads, the Wolverine stack write-up covers the popular BPC-157 plus TB-500 pairing, and the Glow stack piece does the same for the GHK-Cu, BPC-157, and TB-500 combo. The BPC-157 beginner guide is the matching start-here for TB-500's usual partner, and the FDA peptide compounding review explains the July 2026 decision that covers it. The TB-500 library entry is the quick reference for doses, storage, and sources.

How we sourced this, and the fine print

Every claim on this page is pinned to a published source: the animal studies of thymosin beta-4, the FDA compounding record, the Federal Register meeting notice, and the WADA anti-doping list. Where nobody has tested TB-500 in people, this guide says so instead of guessing.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these guides: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 8 entries, primary canon (PubMed, PMC, the FDA, the Federal Register via GovInfo, and USADA) plus one reputable secondary review acknowledged inline, last reviewed 2026-07-13.

Related tools

• Protocol builder overview - Public overview of the Pro protocol builder.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.